Navigation Links
Best Practices Document on Cryoablation Posted on Website of American Urological Association
Date:9/23/2008

IRVINE, Calif., Sept. 23 /PRNewswire-FirstCall/ -- Endocare, Inc. (Nasdaq: ENDO), an innovative medical device company focused on the development of minimally invasive technologies for tissue and tumor ablation, announced today that the American Urological Association (AUA) has for the first time posted on its website the organization's official "best practice" document on cryoablation for prostate cancer, covering primary, salvage and focal cryoablation, also called cryosurgery. The AUA posting of these clinical guidelines is an acknowledgement of the important advances made in the technology of cryoablation, a minimally invasive treatment for prostate cancer that freezes cancerous tumors to destroy them, said Endocare Chairman, President and CEO Craig T. Davenport.

"This is a principled and unbiased assessment of the effectiveness of cryoablation for treating prostate cancer made by the country's most prestigious association of urologists," Davenport said. "The AUA panel that did the assessment looked at all the published studies of cryoablation and came to the conclusion that it is a valuable treatment that should be considered by prostate cancer patients. The publication of these guidelines helps to place cryoablation more squarely in the mainstream of prostate cancer treatments."

The 51-page document, titled "Best Practice Policy Statement on Cryosurgery for the Treatment of Localized Prostate Cancer" and officially adopted at the recent AUA national conference, specifically notes the "seven-to-eight-year biochemical disease free results of cryosurgery. The literature reports that the morbidity profile associated with cryosurgery has improved in all aspects, including continence, rectal/urethral fistula formation, urethral sloughing, and potency in association with the technological advances over the last 10 to 15 years."

About Endocare

Endocare, Inc. -- http://www.endocare.com -- is an innovative medical device company focused on the development of minimally invasive technologies for tissue and tumor ablation. Endocare has initially concentrated on developing technologies for the treatment of prostate cancer and believes that its proprietary technologies have broad applications across a number of markets, including the ablation of tumors in the kidney, lung and liver and palliative intervention (treatment of pain associated with metastases).

Investor Contact: Media Contact:

Matt Clawson Len Hall

Allen & Caron, Inc. Allen & Caron, Inc.

(949) 474-4300 (949) 474-4300

matt@allencaron.com len@allencaron.com

http://www.allencaron.com http://www.allencaron.com

For Additional Information:

Craig T. Davenport, CEO

Michael R. Rodriguez, CFO

Endocare, Inc.

(949) 450-5400

http://www.endocare.com


'/>"/>
SOURCE Endocare, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Campbell Alliance Brand Management and Managed Markets Practices to Speak at CBIs Early Commercialization Conference
2. New Books on Best Practices in Biotechnology Business Development and Biotechnology Education
3. New Study Recognizes Halogen Customer for Best Practices in Employee Performance and Talent Management
4. PAREXEL Experts to Offer Insights Into Outsourcing Best Practices at 17th Annual Partnerships with CROs Conference
5. Genstruct and Sirtris Pharmaceuticals Win Bio-IT Worlds Best Practices Award
6. Best Practices in Quality Assurance and Risk-Based Approach for the Biopharmaceutical Industry
7. Web-Conferences by Best Practices, LLC for July 2008
8. The Michigan Life Sciences Pipeline Announces New Best Practices Seminars Tailored to Michigan Businesses
9. First documented case of pest resistance to biotech cotton
10. Researchers Document Rapid, Dramatic Reverse Evolution in the Threespine Stickleback Fish
11. Impact Systems Announces Completion of Successful Enterprise Content Migrations to Documentum 6
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... ... June 23, 2016 , ... UAS LifeSciences, one of the ... brand, UP4™ Probiotics, into Target stores nationwide. The company, which has been manufacturing ... to its list of well-respected retailers. This list includes such fine stores as ...
(Date:6/23/2016)... - FACIT has announced the creation of a ... Propellon Therapeutics Inc. ("Propellon" or "the Company"), to ... of first-in-class WDR5 inhibitors for the treatment of ... an exciting class of therapies, possessing the potential ... patients. Substantial advances have been achieved with the ...
(Date:6/23/2016)... 23, 2016 Houston Methodist Willowbrook Hospital ... Sports Association to serve as their official health ... Methodist Willowbrook will provide sponsorship support, athletic training ... association coaches, volunteers, athletes and families. ... Sports Association and to bring Houston Methodist quality ...
(Date:6/23/2016)... 2016  The Prostate Cancer Foundation (PCF) is pleased to announce ... cures for prostate cancer. Members of the Class of 2016 were selected from ... Read More About the Class of 2016 PCF Young Investigators ... ... ...
Breaking Biology Technology:
(Date:5/20/2016)... , May 20, 2016  VoiceIt is ... partnership with VoicePass. By working together, ... experience.  Because VoiceIt and VoicePass take slightly different ... engines increases both security and usability. ... excitement about this new partnership. "This ...
(Date:5/3/2016)... , May 3, 2016  Neurotechnology, a ... the MegaMatcher Automated Biometric Identification System (ABIS) ... large-scale multi-biometric projects. MegaMatcher ABIS can process multiple ... using any combination of fingerprint, face or iris ... MegaMatcher SDK and MegaMatcher Accelerator , ...
(Date:4/26/2016)... DUBLIN , April 27, 2016 ... of the  "Global Multi-modal Biometrics Market 2016-2020"  report ... ) , The analysts forecast ... a CAGR of 15.49% during the period 2016-2020.  ... a number of sectors such as the healthcare, ...
Breaking Biology News(10 mins):